JP2024545496A - ヘモグロビンのモジュレーターを投与する方法 - Google Patents

ヘモグロビンのモジュレーターを投与する方法 Download PDF

Info

Publication number
JP2024545496A
JP2024545496A JP2024533948A JP2024533948A JP2024545496A JP 2024545496 A JP2024545496 A JP 2024545496A JP 2024533948 A JP2024533948 A JP 2024533948A JP 2024533948 A JP2024533948 A JP 2024533948A JP 2024545496 A JP2024545496 A JP 2024545496A
Authority
JP
Japan
Prior art keywords
compound
pharma
acceptable salt
dose
per day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024533948A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024545496A5 (https=
JPWO2023107697A5 (https=
Inventor
バース アリーン
ダチン ケン
ビー． ワシントン カーラ
ロ アーサー
Original Assignee
グローバル ブラッド セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グローバル ブラッド セラピューティクス インコーポレイテッド filed Critical グローバル ブラッド セラピューティクス インコーポレイテッド
Publication of JP2024545496A publication Critical patent/JP2024545496A/ja
Publication of JP2024545496A5 publication Critical patent/JP2024545496A5/ja
Publication of JPWO2023107697A5 publication Critical patent/JPWO2023107697A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2024533948A 2021-12-10 2022-12-09 ヘモグロビンのモジュレーターを投与する方法 Pending JP2024545496A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163288377P 2021-12-10 2021-12-10
US63/288,377 2021-12-10
US202263421524P 2022-11-01 2022-11-01
US63/421,524 2022-11-01
US202263429376P 2022-12-01 2022-12-01
US63/429,376 2022-12-01
PCT/US2022/052411 WO2023107697A1 (en) 2021-12-10 2022-12-09 Methods of administering a modulator of hemoglobin

Publications (3)

Publication Number Publication Date
JP2024545496A true JP2024545496A (ja) 2024-12-09
JP2024545496A5 JP2024545496A5 (https=) 2025-10-06
JPWO2023107697A5 JPWO2023107697A5 (https=) 2025-10-06

Family

ID=85108880

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024533948A Pending JP2024545496A (ja) 2021-12-10 2022-12-09 ヘモグロビンのモジュレーターを投与する方法

Country Status (10)

Country Link
US (1) US20250041312A1 (https=)
EP (1) EP4444285A1 (https=)
JP (1) JP2024545496A (https=)
KR (1) KR20240116826A (https=)
AU (1) AU2022408097B2 (https=)
CA (1) CA3241881A1 (https=)
IL (1) IL312835A (https=)
MX (1) MX2024007064A (https=)
TW (1) TW202339732A (https=)
WO (1) WO2023107697A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4727555A1 (en) * 2023-06-13 2026-04-22 Global Blood Therapeutics, Inc. (s)-2-hydroxy-6-((4-(2-(2-hydroxyethyl)nicotinoyl)morpholin-3-yl)methoxy)benzaldehyd for use in the treatment of sickle cell disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
PT3880654T (pt) * 2018-11-19 2022-04-08 Global Blood Therapeutics Inc Compostos de 2-formil-3-hidroxifeniloximetil capazes de modular hemoglobina
EP4337659A1 (en) * 2021-05-14 2024-03-20 Global Blood Therapeutics, Inc. Solid forms of a modulator of hemoglobin

Also Published As

Publication number Publication date
AU2022408097B2 (en) 2026-03-12
TW202339732A (zh) 2023-10-16
KR20240116826A (ko) 2024-07-30
US20250041312A1 (en) 2025-02-06
CA3241881A1 (en) 2023-06-15
EP4444285A1 (en) 2024-10-16
MX2024007064A (es) 2024-06-20
AU2022408097A1 (en) 2024-05-30
IL312835A (en) 2024-07-01
WO2023107697A1 (en) 2023-06-15

Similar Documents

Publication Publication Date Title
WO2021195507A1 (en) Methods and compositions for treating viral infections
WO2012054813A1 (en) Novel methods for treating breathing disorders or diseases
US12171743B2 (en) Forms of aticaprant
JP2024545496A (ja) ヘモグロビンのモジュレーターを投与する方法
EP1772149A1 (en) Drug for prevention or treatment of diabetes
RU2855050C2 (ru) Способы введения модулятора гемоглобина
KR102512518B1 (ko) 페마피브레이트를 함유하는 의약
CN108771662A (zh) 紫檀芪在制备防治高尿酸肾病的药物中的用途
WO2024256964A1 (en) (s)-2-hydroxy-6-((4-(2-(2-hydroxyethyl)nicotinoyl)morpholin-3-yl)methoxy)benzaldehyd for use in the treatment of sickle cell disease
US20230181542A1 (en) Method and pharmaceutical composition for treating chronic kidney disease
CN118369092A (zh) 施用血红蛋白调节剂的方法
HK40107036A (zh) 施用血红蛋白调节剂的方法
TWI741240B (zh) 含有1,4-苯并硫氮呯-1-氧化物衍生物之光學異構物之腎功能障礙的改善藥
TWI802984B (zh) 一種含氮的飽和雜環化合物的應用
WO2024173873A2 (en) Compounds, compositions, and methods for treating, ameliorating, and/or preventing pain
CN121969364A (zh) 用于在治疗重性抑郁障碍中使用的包含阿替卡普兰的组合物
JPWO2005112944A1 (ja) 糖尿病の予防または治療のための薬剤
US20050272814A1 (en) Medicine for prevention or treatment of diabetes
US20060025478A1 (en) Medicine for prevention or treatment of diabetes
HK40084818B (zh) 治疗慢性肾病的方法和药物组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250925

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250925